AOD 9604 is not FDA approved. It has never received approval as a drug for any medical condition, and no active New Drug Application exists for it. The FDA has actually proposed blocking it from being used in pharmacy compounding, citing safety concerns and a lack of sufficient data to confirm it won’t cause harm when administered to humans.
What AOD 9604 Actually Is
AOD 9604 is a synthetic peptide made from a small fragment of human growth hormone, specifically amino acids 177 through 191 from the tail end of the molecule. This fragment was isolated because it appeared to stimulate fat breakdown in fat cells without triggering the other effects of full growth hormone, like increased production of insulin-like growth factor 1 (IGF-1). In laboratory studies, it seemed to work by boosting the activity of certain receptors involved in fat metabolism and by inhibiting an enzyme that promotes fat storage.
The key selling point was always that it could burn fat without the downsides of growth hormone therapy, which include insulin resistance, joint pain, and abnormal tissue growth. Early animal studies were promising enough that an Australian company, Metabolic Pharmaceuticals, took it into human clinical trials as an obesity treatment.
Why Clinical Trials Failed
Metabolic Pharmaceuticals ran a Phase 2B clinical trial, the stage where a drug needs to demonstrate it actually works at specific doses before advancing toward approval. The results were definitive, and not in the drug’s favor. Weight loss across all dose groups was less than 1 kilogram compared to placebo after both 12 and 24 weeks of treatment. That difference was too small to reach statistical significance, meaning the drug couldn’t be distinguished from doing nothing.
The company noted that the placebo group (which received diet and exercise guidance but no drug) lost substantial weight on their own, which may have obscured any small drug effect. Regardless, the company terminated development and stated the results “do not support the commercial viability of the drug as a treatment for obesity.” No other company has since taken AOD 9604 through the FDA drug approval process.
The FDA’s Current Position
The FDA has taken a notably cautious stance on AOD 9604. The agency has identified “no, or only limited, safety-related information” and stated it “lacks sufficient information to know whether the drug would cause harm when administered to humans.” It also flagged serious adverse events that may be associated with the peptide, though it noted causality isn’t clear.
Beyond the safety concerns, the FDA has raised specific issues about the risk of immune reactions (immunogenicity) for certain routes of administration and about difficulties in characterizing the purity of the peptide itself. Peptides are complex molecules, and impurities introduced during manufacturing can pose their own health risks.
The FDA’s Pharmacy Compounding Advisory Committee has reviewed AOD 9604 for potential inclusion on the list of bulk substances that compounding pharmacies can use under Section 503A of federal law. The FDA proposed that neither AOD 9604 (free base) nor AOD 9604 acetate be included on that list. If finalized, this would mean compounding pharmacies could not legally use it to make custom prescriptions under the standard compounding exemptions. No GRAS (“Generally Recognized as Safe”) notification has been filed for it with the FDA either.
What the Safety Data Shows
Six randomized, double-blind, placebo-controlled trials were conducted during AOD 9604’s clinical development. These studies specifically looked for the problems associated with full growth hormone treatment: elevated IGF-1 levels, insulin resistance, and impaired blood sugar handling. None of those effects appeared. The peptide did not raise IGF-1 levels, did not worsen carbohydrate metabolism, and produced no detectable antibodies in tested patients, suggesting the immune system wasn’t reacting to it.
No serious adverse events related to AOD 9604 occurred during these controlled trials, and the overall side effect profile was described as “indistinguishable from placebo.” That sounds reassuring, but there’s an important caveat: these were relatively short studies with limited participants, conducted under controlled conditions. The FDA’s concern isn’t necessarily that the drug caused obvious harm in trials. It’s that not enough is known about long-term use, varying doses, different administration routes, and the quality of the peptide as it’s actually being sold and compounded today, often far outside the conditions of those original studies.
Where People Are Getting It
Despite its lack of approval, AOD 9604 is widely available through compounding pharmacies, anti-aging clinics, and online peptide vendors. It’s typically sold as a subcutaneous injection, though oral forms exist as well. The products being sold today are not manufactured under the same quality controls as FDA-approved drugs, and the peptide purity and dosing can vary significantly between sources.
This is the core regulatory tension. A substance that failed its pivotal efficacy trial, was abandoned by its developer, and has been flagged by the FDA as potentially risky is nonetheless being marketed and prescribed, often for the same purpose (fat loss) that clinical trials showed it couldn’t meaningfully achieve.
AOD 9604 and Athletic Use
The World Anti-Doping Agency (WADA) prohibits AOD 9604 at all times for competitive athletes. It falls under WADA’s “non-approved substances” category, which bans any pharmacological substance that has no current approval by any governmental health authority for human therapeutic use. This includes drugs that are under development, discontinued, or approved only for veterinary use. Since AOD 9604 was discontinued after failing clinical trials and has never been approved anywhere in the world for human use, it is prohibited in all competitive sports governed by WADA rules.
Athletes who test positive for AOD 9604 face the same sanctions as for any other prohibited substance, regardless of whether it provided any actual performance benefit. The ban is based on its regulatory status, not on proven ergogenic effects.